Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rostaporfin - Adgero Biopharmaceuticals

Drug Profile

Rostaporfin - Adgero Biopharmaceuticals

Alternative Names: PhotoPoint SnET2; Photrex; Purlytin; REM-001; REM-001 Therapy; Rostaporfin-PDT; Sn(IV) etiopurpurin; SnET2; SnET2-PDT; Tin ethyl etiopurpurin

Latest Information Update: 26 Feb 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator
  • Developer Adgero Biopharmaceuticals; Miravant Medical Technologies
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Lipid peroxidation stimulants; Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Basal cell nevus syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer
  • Phase I/II Basal cell cancer
  • No development reported Age-related macular degeneration; Psoriasis
  • Discontinued Benign prostatic hyperplasia; Brain cancer; Coronary artery restenosis; Diabetic retinopathy; Glaucoma; Head and neck cancer; Kaposi's sarcoma; Lung cancer; Prostate cancer; Skin cancer

Most Recent Events

  • 22 Feb 2018 REM-001 therapy receives Orphan Drug status for Basal Cell Nevus Syndrome in USA
  • 10 Apr 2017 Efficacy data from the phase II/III trials in Breast cancer released by Adgero Biopharmaceuticals
  • 05 Jan 2017 Phase-I/II clinical trials in Basal cell cancer (Recurrent) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top